Results 91 to 100 of about 14,924 (223)

EVOLUTION OF HYPOGAMMAGLOBULINEMIA IN PREMATURE AND FULL-TERM INFANTS

open access: yes, 2011
There are few data in the literature reporting the evolution of hypogammaglobulinemia in premature and full-term infants during the first years of life.
PICCINNO, VALENTINA   +5 more
core  

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

open access: yesMuscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier   +7 more
wiley   +1 more source

Secondary hypogammaglobulinemia in Waldmann's disease treated with subcutaneous immunoglobulins [PDF]

open access: yes, 2016
Primary intestinal lymphangiectasia (PIL) is rare disorder characterized by congenital malformation or obstruction of intestinal lymphatic drainage; it is responsible for protein losing enteropathy leading to lymphopenia, hypoalbuminemia and ...
PATUZZO, Giuseppe   +4 more
core   +1 more source

Infant with hypogammaglobulinemia

open access: yes
Dojenče s recidivnim respiratornim infekcijama čest je problem u svakodnevnoj pedijatrijskoj praksi, što zbog nejasne definicije zdravog dojenčeta, što zbog mogućih ozbiljnih osnovnih bolesti, ali i složene dijagnostičke obrade koja često zahtijeva ...
Navratil, Marta
core   +1 more source

Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma

open access: yesEuropean Journal of Haematology, Volume 116, Issue 6, Page 797-805, June 2026.
ABSTRACT Objectives CAR‐T cell therapies such as lisocabtagene maraleucel (liso‐cel) have transformed the treatment of patients with second line primary refractory or early relapsed ≤ 12 months (R/R) large B‐cell lymphoma (LBCL). The objective of this study was to assess the cost‐effectiveness of liso‐cel compared to standard of care (SOC) to treat R/R
Catherine Thieblemont   +6 more
wiley   +1 more source

Reply to “Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence”

open access: yes
Annals of Neurology, Volume 99, Issue 6, Page 1614-1615, June 2026.
Gabriel Cerono   +3 more
wiley   +1 more source

A Late-Diagnosed Case of Common Variable Immunodeficiency

open access: yesAhi Evran Medical Journal
Common Variable Immunodeficiency (CVID) is the most common form of primary immunodeficiency (PID). CVID is characterized by decreased serum immunoglobulin levels, decreased or absent antibody production, and normal or low B-lymphocyte counts.
Coşkun Doğan   +2 more
doaj   +1 more source

Multisystem disorder associated with a pathogenic variant in CLCN7 in the absence of osteopetrosis

open access: yesMolecular Genetics & Genomic Medicine
Background We clinically and genetically evaluated a Taiwanese boy presenting with developmental delay, organomegaly, hypogammaglobulinemia and hypopigmentation without osteopetrosis.
Chung‐Lin Lee   +8 more
doaj   +1 more source

Rituximab unveils hypogammaglobulinemia and immunodeficiency in children with autoimmune cytopenia

open access: yes, 2019
Rituximab (RTX; anti-CD20 monoclonal antibody) is a treatment option in children with refractory immune thrombocytopenia (ITP), autoimmune haemolytic anaemia (AHA) and Evans syndrome (ES).
Barzaghi, Federica   +26 more
core   +1 more source

Rituximab-induced IgG hypogammaglobulinemia in children with nephrotic syndrome and normal pre-treatment IgG values

open access: yes, 2019
BACKGROUND In paediatric patients with complicated nephrotic syndrome (NS), rituximab (RTX) administration can induce persistent IgG hypogammaglobulinemia among subjects showing low basal immunoglobulin G (IgG) levels.
Marzuillo P.   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy